ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2013
Expression and prognostic role of c-Myb as a novel cell cycle protein in esophageal squamous cell carcinoma.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.
- Pooled it
- Molecular dynamics simulation reveals DNA-specific recognition mechanism via c-Myb in pseudo-palindromic consensus ofJournal of Zhejiang University. Science. B · 2023Article
- Transcription factor c-Myb: novel prognostic factor in osteosarcoma.Clinical & experimental metastasis · 2022Article
- c-Myb facilitates immune escape of esophageal adenocarcinoma cells through the miR-145-5p/SPOP/PD-L1 axis.Clinical and translational medicine · 2021Article
- High c-Myb Expression Associates with Good Prognosis in Colorectal Carcinoma.Journal of Cancer · 2019Article
- c-MYB and DMTF1 in Cancer.Cancer investigation · 2019Review
- Integrative analysis of copy number and transcriptional expression profiles in esophageal cancer to identify a novel driver gene for therapy.Scientific reports · 2017Article
- Dact3 inhibits the malignant phenotype of non-small cell lung cancer through downregulation of c-Myb.International journal of clinical and experimental pathology · 2017Article
- MicroRNA-503 represses epithelial-mesenchymal transition and inhibits metastasis of osteosarcoma by targeting c-myb.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- MicroRNA-103a inhibits gastric cancer cell proliferation, migration and invasion by targeting c-Myb.Cell proliferation · 2015Article
- MicroRNA-424 is down-regulated in hepatocellular carcinoma and suppresses cell migration and invasion through c-Myb.PloS one · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe c-Myb transcription factor controls differentiation and proliferation in hematopoietic and other cell types, and has latent in regulation during the cell cycle. Recent studies suggested that deregulation of c-Myb expression plays a key role in oncogenesis. To investigate the potential roles of c-Myb in esophageal carcinoma, expression of c-Myb was examined in human esophageal carcinoma samples.
methodsImmunohistochemistry and Western blot analysis were performed for c-Myb in 87 esophageal carcinoma samples. The data were correlated with clinicopathological features. The univariate and multivariate survival analyses were also performed to determine their prognostic significance.
resultsc-Myb was overexpressed in esophageal carcinoma as compared with the adjacent normal tissue. High expression of c-Myb was associated with histological grade and was positively correlated with proliferation marker Ki-67 (P = 0.001). Univariate analysis showed that c-Myb expression was associated with poor prognosis (P < 0.001). Multivariate analysis indicated that c-Myb was an independent prognostic marker for esophageal carcinoma (P < 0.001). While in vitro, following release from serum starvation of TE-1 esophageal carcinoma cell, the expression of c-Myb was upregulated.
conclusionsOur results suggested that c-Myb overexpression is involved in the pathogenesis of esophageal carcinoma; it may be a favorable independent poor prognostic parameter for esophageal carcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.